Navigation Links
Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome

f this syndrome, there are no treatments specifically approved for FMS in the United States or elsewhere and the addressable patient population is not yet well established. For more information about fibromyalgia, visit http://www.fmsresource.com.

About Cypress

Cypress is committed to be the innovator and leader in providing products that improve the treatment of Functional Somatic Syndromes and other central nervous system conditions, including fibromyalgia syndrome. Cypress' strategy involves acquiring/in-licensing undervalued central nervous system active compounds and developing them for new indications.

For more information about Cypress, please visit Cypress' web site at www.cypressbio.com.

This press release, as well as Cypress' SEC filings and web site at http://www.cypressbio.com, contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including statements about the potential of milnacipran to treat Fibromyalgia Syndrome and our planned NDA filing for milnacipran. Actual results could vary materially from those described as a result of a number of factors, including those set forth in Cypress Annual Report on Form 10-K, the most recent Quarterly Report on Form 10-Q and any subsequent SEC filings and including, but not limited to, that more detailed analysis of the trial results may not be favorable or may lead to different conclusions; the FDA may not accept our first Phase III clinical trial as one of the two pivotal trials required for NDA approval, that upon further reflection that we may determine not to submit an NDA in 2007, that we may not be able to protect our milnacipran patent portfolio and that milnacipran may never be approved as a drug by the FDA.

About Forest Laboratories and Its Pro
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
2. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
6. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:7/10/2014)... July 10, 2014 Yesterday, former Congressman ... medical device manufacturing facility. Rep. Kennedy and ... monitors facilitate cutting-edge research in neurological disease and ... mental health advocate, Garen Staglin , created ... fostering fundamental changes that will radically accelerate the ...
(Date:7/10/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... completed the sale to Galderma of all rights to ... by Valeant for $1.4 billion in cash, pursuant to ... completed its acquisition of Galderma. "We ... to a company that is firmly committed to the ...
(Date:7/10/2014)... BURLINGTON, Mass. , July 10, 2014 /PRNewswire/ ... three-quarters of surveyed infectious disease (ID) specialists are ... Medicines Company,s Orbactiv (oritavancin) for use as OPAT, ... to prescribe these agents to their hospital inpatients. ... percent) of OPAT patients are initiated on OPAT ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... CITY, Calif., Feb. 17, 2012 Codexis, Inc. (NASDAQ: ... to enable the production of biofuels, bio-based chemicals, and ... of Directors has appointed Peter Strumph as the company,s ... as President and Chief Executive Officer and from the ...
... Pharmaceuticals Holdings (Nasdaq: ENDP ) today announced that ... overview at the J.P. Morgan Annual Global High Yield & ... a.m. ET.  The conference will be held at the Loews ... and audio archive of the presentation will be available on ...
Cached Medicine Technology:Codexis Appoints Interim Chief Executive Officer 2
(Date:7/12/2014)... (PRWEB) July 12, 2014 The report, ... Alkyd Resins) Market by Application & Geography – Trends ... market with analysis and forecasting of market volume and ... of the derivatives separately. The market of phthalic anhydride ... in 2013 to $8,415.89 million by 2018, with a ...
(Date:7/12/2014)... 2014 In this cognitive ... assessment and training’ is defined as solution ... or enhance cognitive functions. These solutions are ... dementia screening, clinical trials, driver’s safety, rehabilitation, ... assessment, brain training, and employers’ assessment and ...
(Date:7/12/2014)... The fastest-growing mobile technology is LTE (Long Term Evolution). ... continues to grow due to the rapid evolution of ... data traffic, which is a major driver for the ... Measurement equipment comply with industry standards, and services which ... Market is estimated to grown from $3.75 billion in ...
(Date:7/12/2014)... 2014 (HealthDay News) -- If you make exercise fun, you,ll ... one experiment, 56 adults were led on a 1.4-mile walk ... or a scenic walk. The participants were given lunch after ... exercise outing ate 35 percent more chocolate pudding for dessert ... In another experiment, 46 adults were given mid-afternoon snacks ...
(Date:7/12/2014)... 2014 Sean Francis, owner of the Kawartha Lakes ... to his clients. He’s also known for his support of local ... way to combine the two and is excited to announce that ... Boys and Girls Club. , The funds are the result of ... 23rd. Francis sent out emails and asked his clients to put ...
Breaking Medicine News(10 mins):Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 5Health News:Make Exercise Fun, Eat Less Afterwards 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 3
... Calif., Nov. 19 ,Natrol, Inc, (Nasdaq: NTOL ... nutritional products, and Gener8Xion Entertainment, Inc.,(OTC Bulletin Board: ... a letter of intent for a strategic,alliance to ... intends to,exclusively license the "Living Pure" brand to ...
... as World,s Leading Thoroughbred ... Radiography Review, SANTA CLARA, Calif., Nov. 19 ... doors to the,annual September Yearling Sale, the medical repository ... medical images. Beginning with 12,review workstations from Eklin Medical ...
... HCA Study Reveals Qualities of High-Performing Organizations, ... from The Beryl,Institute, titled "High Performing Organizations: Culture ... satisfaction are highly,correlated with outstanding clinical care and ... bottom line. Using the,results of a study done ...
... Nov. 19 Boston Scientific,Corporation (NYSE: BSX ... been,reached to settle claims associated with a series ... and 2006. Boston Scientific acquired,Guidant last year. This ... July 2007 to cover additional unanticipated claims. ...
... - ... 8,550 Patient Plaintiffs -, MINNEAPOLIS, Nov. 19 ... Medical Device Litigation,announced today that an amended settlement agreement ... asserted claims against Guidant,Corporation, Boston Scientific Corporation and other ...
... Flagship Global Health,Inc. (OTC Bulletin Board: FGHH), a ... priority access to, the world,s leading,doctors has added ... and services field to lead its Marketing and ... marketing and sales at Flagship,Global Health and, in ...
Cached Medicine News:Health News:Natrol, Inc. (Nasdaq: NTOL) and Gener8Xion Entertainment (BB: GNXE) Announce Strategic Alliance to Create a New Health and Wellness Division 2Health News:Natrol, Inc. (Nasdaq: NTOL) and Gener8Xion Entertainment (BB: GNXE) Announce Strategic Alliance to Create a New Health and Wellness Division 3Health News:Natrol, Inc. (Nasdaq: NTOL) and Gener8Xion Entertainment (BB: GNXE) Announce Strategic Alliance to Create a New Health and Wellness Division 4Health News:Keeneland Scales Eklin Digital Repository(TM) to 32 Medical Image Review Workstations 2Health News:Keeneland Scales Eklin Digital Repository(TM) to 32 Medical Image Review Workstations 3Health News:Boston Scientific Announces Amended Agreement to Settle Product Lawsuits 2Health News:Boston Scientific Announces Amended Agreement to Settle Product Lawsuits 3Health News:Plaintiffs Obtain $240 Million Amended Settlement In Guidant Defibrillators Products Liability Litigation 2Health News:Flagship Global Health Hires Health Care Veteran Larsen to Head Marketing and Sales 2
The CGPL capsulotomy contact glass was designed by Riquin, Fankhauser et al. for the dissection of opacified posterior lens capsules and membranes in the pupillary and retropupillary space with the Y...
The CGAL gonioscopic contact glass was designed by Roussel and Fankhauser for,laser treatments of the chamber angle. It reduces the laser spot by a factor of 1.5 as compared to a Goldmann Glass....
The CGRL is a Wide Angle Contact Glass designed for laser photocoagulation and diagnosis of the retina....
The classic Goldmann Glass. Designed to work with argon/YAG Lasers....
Medicine Products: